Cervical Cancer Vaccines Could Be Cost-Effective For Developing Countries, Researchers Say

Cervical cancer vaccines from Merck and GlaxoSmithKline could be cost-effective if subsidies or new prices are created so developing countries can afford them, researchers said Thursday at the World Cancer Congress in Geneva, Reuters reports.

More: continued here

Filed under: Cervical Cancer on September 8th, 2008